International Union of Biochemistry and Molecular Biology

aTyr Pharma to Highlight Advancements in tRNA Synthetase Biology Research at the 13th International Symposium of Aminoacyl-tRNA Synthetases (AARS 2023)

Retrieved on: 
Tuesday, June 6, 2023

SAN DIEGO, June 06, 2023 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a clinical stage biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced multiple presentations at the International Union of Biochemistry and Molecular Biology’s 13th International Symposium of Aminoacyl-tRNA Synthetases (AARS 2023), which is scheduled to take place June 4 – 9 in Ontario, Canada.

Key Points: 
  • Conference hosted by the International Union of Biochemistry and Molecular Biology (IUBMB) to feature leading research in tRNA synthetase biology.
  • Presentations showcase company’s progress in generating new therapeutics from tRNA synthetase platform.
  • “As a leader in the field of tRNA biology, we look forward to highlighting some of the recent findings from our platform at AARS 2023,” said Leslie A. Nangle, Ph.D., Vice President, Research at aTyr.
  • aTyr is focused on elucidating novel pathways mediated through extracellular tRNA synthetases and creating new biologics to modulate these pathways by developing protein therapies based on extracellular tRNA synthetase fragments.

Insights on the Potato Protein Global Market to 2027 - Shifting Consumer Preference Toward Vegan Dietary Patterns Drive Growth - ResearchAndMarkets.com

Retrieved on: 
Thursday, January 12, 2023

Potato protein is the dry by-product collected during the generation and separation of potato starch.

Key Points: 
  • Potato protein is the dry by-product collected during the generation and separation of potato starch.
  • It is a rich source of digestible protein and amino acid profile and is extracted from potato juice through precipitation and centrifugation.
  • Potato protein is commonly available in concentrated, isolated and hydrolyzed variants and is widely used as an alternative to animal-sourced proteins.
  • With the shifting consumer preference toward vegan dietary patterns, there is a rising demand for potato protein as an effective source of plant-based protein.

TFF Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update

Retrieved on: 
Monday, November 14, 2022

FORT WORTH, Texas, Nov. 14, 2022 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today reported financial results for the third quarter of 2022 and provided an update on recent corporate and clinical developments. The Company will discuss the highlights on a conference call and webcast, scheduled for today, Monday, November 14, 2022, at 4:30 PM ET.

Key Points: 
  • We have recently announced positive proof of concept data from two patients in our TFF Voriconazole compassionate use program, said Glenn Mattes, Chief Executive Officer of TFF Pharmaceuticals.
  • The Company will host a conference call today, Monday, November 14, 2022, at 4:30 PM, Eastern Time, to discuss third quarter 2022 financial results and the business update.
  • For the quarter ended September 30, 2022, compared to quarter ended September 30, 2021
    Cash Position: As of September 30, 2022, TFF Pharmaceuticals reported cash and cash equivalents of $13.1 million.
  • Net Loss: TFF Pharmaceuticals reported a net loss for the third quarter of 2022 of $7.3 million, compared to a net loss of $8.7 million in 2021.

TFF Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update

Retrieved on: 
Thursday, August 11, 2022

FORT WORTH, Texas, Aug. 11, 2022 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today reported financial results for the second quarter of 2022 and provided an update on recent corporate and clinical developments. The Company will discuss the highlights on a conference call and webcast, scheduled for today, Thursday, August 11, 2022, at 4:30 PM ET.

Key Points: 
  • We believe the second half of the year is shaping up to be a very exciting period for TFF Pharmaceuticals.
  • Research and Development (R&D) expenses: R&D expenses for the second quarter of 2022 were $5.1 million, compared to $2.8 million in 2021.
  • General & Administrative (G&A) expenses: G&A expenses for the second quarter of 2022 were $3.7 million, compared to $2.4 million in 2021.
  • Net Loss: TFF Pharmaceuticals reported a net loss for the second quarter of 2022 of $8.7 million, compared to a net loss of $4.7 million in 2021.

Global Food Extrusion Market Forecast to 2026: $99.7 Billion Trend and Opportunity Assessment - ResearchAndMarkets.com

Retrieved on: 
Wednesday, October 13, 2021

The global food extrusion market is estimated to be valued at USD 73.1 billion in 2021, and is projected to reach USD 99.7 billion by 2026, recording a CAGR of 6.4% during the forecast period.

Key Points: 
  • The global food extrusion market is estimated to be valued at USD 73.1 billion in 2021, and is projected to reach USD 99.7 billion by 2026, recording a CAGR of 6.4% during the forecast period.
  • The food extrusion market in the food industry has been growing in accordance with the processed food industry.
  • In developing countries, the food extrusion market is also evolving in response to the rapidly increasing demand for convenience product type options.
  • The report segments the food extrusion market on the basis of food products types, by extruders, by process, and regions.